Of course earnings are going to be the main driver, and even...

Of course earnings are going to be the main driver, and even further down the track FDA approval, but as to a near term catalyst for some positive move I think inclusion into the ASX 300 could have the potential to be a pleasant surprise.
I'm pretty sure ASX 300 inclusion would make it available to a whole lot more funds than simply All Ords inclusion, and as I said due to the thin volume being traded, it wouldn't take very many newly interested parties to get it going in the right direction.
As to dropping 20% after All Ords inclusion. I think that's probably more to do with the fact that it happened smack bang in the middle of the major dowtrend/selldown since first approval back in Oct/Nov 2014. Knowing that there was someone there willing to sell off into any strength certainly wasn't helping sentiment towards the stock at the time.
Anyway I guess its all academic because as I said it may not even happen, but something else to maybe look forward to.